Dysmenorrhea Treatment Market grow exponentially at US$ 8.40 billion by 2023, registering a fabulous CAGR approximately 12.28% throughout the forecast period

Global Dysmenorrhea Treatment Market is expected to reach US$ 8.40 billion in 2023 from US$ 5.68 billion in 2016 with a CAGR of approximately 12.28% during the forecast period 2017-2023.

Pain during menstruation is known as dysmenorrhea. Increase in incidence of dysmenorrhea, which is attributed to changing lifestyle, addiction to smoking and alcohol, hormonal changes and physical and mental stress, favor the growth of this market. Additionally, lack of awareness regarding reproductive health and increase in first pregnancy age, favor the growth of this market.

Key players in Dysmenorrhea Treatment market are: Novartis AG (Switzerland), Merck, Inc. (U.S), Bayer Schering Pharma AG (Germany), Abbott Healthcare (U.S), Pfizer, Inc. (U.S). Other players include F. Hoffmann-La Roche Ltd (U.S), Sanofi (U.S), Taj Pharmaceuticals, Ltd (India).

Get Sample Research Report at https://www.marketresearchfuture.com/sample_request/727

Novartis AG is a multinational pharmaceutical company. It is one of the largest pharmaceutical companies in the world. The company excels in research & development activities in various branches of healthcare using science based innovations and new business approaches. CATAFLAM is a drug for treating primary dysmenorrhea.

Merck Inc. is a largest pharmaceutical company in the world. It manufactures medicines, vaccine and animal health products. The company produce products for key therapeutic areas like oncology, immunology, neuroscience, cardiovascular disease, respiratory disease, infectious disease, and women's health. “Cyclessa” is a drug manufactured by this company for prevention of pregnancy as a method of contraception.

Bayer Schering Pharma is a German chemical, pharmaceutical and Life Science Company. In June 2017, the company announced the launch of “Dan E Fu Kang ointment” for the treatment of menstrual disorders. It established a partnership with Dayima, a women health management platform in India.

Abbott Healthcare is a global healthcare and research company. Flurbiprofen is a non-steroidal anti-inflammatory agent prescribed for pain raising from dysmenorrhea.

Brows Full Detailed Report at https://www.marketresearchfuture.com/reports/dysmenorrhea-treatment-market-727

Globally, Dysmenorrhea Treatment market is spread across four regions America, Europe, Asia-Pacific and Middle East and Africa. North America is the largest market for dysmenorrhea. The factor contributing for the growth of this market is an increase in problems with reproductive healthy among women and changing lifestyle. Asia Pacific is expected to be the fastest growing market for dysmenorrhea treatment. India is expected to be the emerging and fastest growing region. The market shows steady growth in Middle East and Africa.

Intended Audience

Dysmenorrhea medicine suppliers
Dysmenorrhea medicine manufacturers
Research and Development (R&D) Companies
Medical Research Laboratories
Diagnostic centers
Academic Medical Institutes and Universities

Inquire for discount at https://www.marketresearchfuture.com/check-discount/727

About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.